Mesoblast (MEOBF) Stock Price, News & Analysis

Company Overview

Mesoblast Limited (OTCMKTS:MEOBF) is a global leader in regenerative medicine focused on the development and commercialization of innovative allogeneic cell therapies. The company’s proprietary platform harnesses mesenchymal lineage adult stem cells to address a range of inflammatory and immunological conditions. Mesoblast’s pipeline includes multiple late-stage and marketed products that target serious diseases with high unmet medical needs.

The company’s lead product, remestemcel-L (Ryvicor/Ryoncil), is under development for the treatment of steroid-refractory acute graft versus host disease in pediatric patients and has received conditional approval for certain indications in Japan. Additional programs in advanced clinical stages include therapies for chronic heart failure, acute respiratory distress syndrome, and chronic lower back pain. Mesoblast’s allogeneic approach is designed to enable “off-the-shelf” dosing, offering potential advantages in consistency, scalability, and rapid availability compared to patient-specific cell therapies.

Founded in 2004 and headquartered in Melbourne, Australia, Mesoblast operates research, development, and manufacturing facilities across multiple geographies, including the United States and Europe. The company has established strategic collaborations and licensing agreements with leading pharmaceutical companies and health authorities worldwide to advance development programs and secure regulatory approvals. Mesoblast’s global footprint supports its commitment to making cell therapy more broadly accessible to patients in need.

Mesoblast’s leadership team comprises experienced professionals from the biotechnology and pharmaceutical industries. The company was co-founded by Dr. Silviu Itescu, who has led the scientific strategy and clinical development efforts. Under the guidance of its executive management and board of directors, Mesoblast continues to expand its pipeline and pursue regulatory milestones, with a focus on delivering transformative medicines for serious diseases.

Key Stats

• Today's Range: $1.68 to $1.68
• 50-Day Range: $1.45 to $2.12
• 52-Week Range: $0.91 to $5.34
• Volume: 9,256 shs
• Average Volume: 77,756 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MEOBF Stock Analysis - Frequently Asked Questions

How have MEOBF shares performed this year?

Mesoblast's stock was trading at $2.20 at the beginning of 2025. Since then, MEOBF shares have decreased by 23.6% and is now trading at $1.68.

How do I buy shares of Mesoblast?

Shares of MEOBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:MEOBF
• CIK: 1345099
• Web: www.mesoblast.com
• Phone: (139) 639-6036
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A